First In Human Study of CX-2051 in Advanced Solid Tumors

Recruiting now · Phase 1

Conditions studied: Solid Tumor, Adult

In brief

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.

Key facts

Study ID

NCT06265688

Run by

CytomX Therapeutics

People needed

160

Starts

2024-04-02

Expected to finish

2029-03-31

Last updated by the study team

2026-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Measurable disease per RECIST v1.1
• Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue
• Additional inclusion criteria may apply

You may not qualify if…

• Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated
• Known active central nervous system (CNS) involvement by malignancy
• Systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to C1D1
• Previous treatment with antibody-drug conjugates (ADCs) with Topo-I inhibitor payload
• Major surgery (requiring general anesthesia) within 4 weeks prior to C1D1
• Elevated baseline laboratory values
• Serious concurrent illness
• Pregnant or breast feeding
• Additional exclusion criteria may apply

Where it is running

• Sarah Cannon Research Institute at HealthONE — Denver, Colorado, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Montefiore Medical Center — The Bronx, New York, United States (enrolling)
• Carolina BioOncology Institute, PLLC — Huntersville, North Carolina, United States (enrolling)
• Sarah Cannon Research Institute, LLC — Nashville, Tennessee, United States (enrolling)
• START - Dallas/Fort Worth — Fort Worth, Texas, United States (enrolling)
• START San Antonio LLC — San Antonio, Texas, United States (enrolling)
• NEXT Virginia — Fairfax, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.